Two founder mutations in the alpha-tropomyosin and the cardiac myosin-binding protein C genes are common causes of hypertrophic cardiomyopathy in the Finnish population

References

• Landstrom AP, Ackerman MJ. Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. Circulation. 2010;122:2441–9.
   PubMedGoogle Scholar
• Ho CY. Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation. 2010;122:2430–40.
   PubMedGoogle Scholar
• Richard P, Charron ,P, Carrier L, Ledeuil C, Cheav T, Pichereau C, . Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107:2227–32.
   PubMed Web of Science ®Google Scholar
• Erdmann J, Daehmlow S, Wischke S, Senyuva M, Werner U, Raible J, . Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet. 2003;64:339–49.
   PubMed Web of Science ®Google Scholar
• Van Driest SL, Ellsworth EG, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy. Circulation. 2003;108:445–51.
   PubMedGoogle Scholar
• Girolami F, Olivotto I, Passerini I, Zachara E, Nistri S, Re F, . A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy. J Cardiovasc Med (Hagerstown). 2006;7:601–7.
   PubMed Web of Science ®Google Scholar
• Andersen PS, Havndrup O, Hougs L, Sørensen KM, Jensen M, Larsen LA, . Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives. Hum Mutat. 2009;30:363–70.
   PubMed Web of Science ®Google Scholar
• Alders M, Jongbloed R, Deelen W, van den Wijngaard A, Doevendans P, Ten Cate F, . The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J. 2003;24:1848–53.
   PubMed Web of Science ®Google Scholar
• Kubo T, Kitaoka H, Okawa M, Matsumura Y, Hitomi N, Yamasaki N, . Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac myosin-binding protein C gene among Japanese. J Am Coll Cardiol. 2005;46:1737–43.
   PubMed Web of Science ®Google Scholar
• Moolman-Smook JC, De Lange WJ, Bruwer EC, Brink PA, Corfield VA. The origins of hypertrophic cardiomyopathy-causing mutations in two South African subpopulations: a unique profile of both independent and founder events. Am J Hum Genet. 1999;65:1308–20.
   PubMed Web of Science ®Google Scholar
• Marjamaa A, Salomaa V, Newton-Cheh C, Porthan K, Reunanen A, Karanko H, . High prevalence of four long QT syndrome founder mutations in the Finnish population.Ann Med. 2009;41:234–40.
   PubMed Web of Science ®Google Scholar
• Jääskeläinen P, Miettinen R, Kärkkäinen P, Toivonen L, Laakso M, Kuusisto J. Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes. Ann Med. 2004;36:23–32.
   PubMed Web of Science ®Google Scholar
• Thierfelder L, Watkins H, MacRae C, Lamas R, McKenna W, Vosberg HP, . Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994;77:701–12.
   PubMed Web of Science ®Google Scholar
• Jääskeläinen P, Soranta M, Miettinen R, Saarinen L, Pihlajamäki J, Silvennoinen K, . The cardiac beta-myosin heavy chain gene is not the predominant gene for hypertrophic cardiomyopathy in the Finnish population. J Am Coll Cardiol. 1998;32:1709–16.
   PubMed Web of Science ®Google Scholar
• Jääskeläinen P, Kuusisto J, Miettinen R, Kärkkäinen P, Kärkkäinen S, Heikkinen S, . Mutations in the cardiac myosin-binding protein C gene are the predominant cause of familial hypertrophic cardiomyopathy in eastern Finland. J Mol Med. 2002;80:412–22.
   PubMed Web of Science ®Google Scholar
• Christiaans I, Nannenberg EA, Dooijes D, Jongbloed RJ, Michels M, Postema PG, . Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands. Neth Heart J. 2010;18:248–54.
   PubMed Web of Science ®Google Scholar
• Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, . American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687–713.
   PubMed Web of Science ®Google Scholar
• van den Wijngaard A, Volders P, Van Tintelen JP, Jongbloed JD, van den Berg MP, Lekanne Deprez RH, . Recurrent and founder mutations in the Netherlands: cardiac Troponin I (TNNI3) gene mutations as a cause of severe forms of hypertrophic and restrictive cardiomyopathy. Neth Heart J. 2011;19:344–51.
   PubMed Web of Science ®Google Scholar
• Oliva-Sandoval MJ, Ruiz-Espejo F, Monserrat L, Hermida-Prieto M, Sabater M, García-Molina E, . Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. Heart. 2010;96: 1980–4.
   PubMed Web of Science ®Google Scholar
• Coviello DA, Maron BJ, Spirito P, Watkins H, Vosberg HP, Thierfelder L, . Clinical features of hypertrophic cardiomyopathy caused by mutation of a “hot spot” in the alpha-tropomyosin gene. J Am Coll Cardiol. 1997;29:635–40.
   PubMed Web of Science ®Google Scholar
• Nakajima-Taniguchi C, Matsui H, Nagata S, Kishimoto T, Yamauchi-Takihara K. Novel missense mutation in alpha-tropomyosin gene found in Japanese patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol. 1995;27:2053–8.
   PubMed Web of Science ®Google Scholar
• Rudziński T, Selmaj K, Drozdz J, Krzemińska-Pakuła M. Selected mutations in the myosin binding protein C gene in the Polish population of patients with hypertrophic cardiomyopathy. Kardiol Pol. 2008;66:821–5.
   PubMed Web of Science ®Google Scholar
• Michels M, Soliman OI, Phefferkorn J, Hoedemaekers YM, Kofflard MJ, Dooijes D, . Disease penetrance and risk stratification for sudden cardiac death in asymptomatic hypertrophic cardiomyopathy mutation carriers. Eur Heart J. 2009;30:2593–8.
   PubMed Web of Science ®Google Scholar
• Bottinelli R, Coviello DA, Redwood CS, Pellegrino MA, Maron BJ, Spirito P, . A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ Res. 1998;82:106–15.
   PubMed Web of Science ®Google Scholar
• van Dijk SJ, Dooijes D, dos Remedios C, Michels M, Lamers JM, Winegrad S, . Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 2009;119:1473–83.
   PubMed Web of Science ®Google Scholar
• Olivotto I, Girolami F, Ackerman MJ, Nistri S, Bos JM, Zachara E, . Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2008;83:630–8.
   PubMed Web of Science ®Google Scholar